NeoProbe gains another US patent for radio-immunoguided surgery (RIGS)
This article was originally published in Clinica
NeoProbe has been awarded a US patent for "biostaging" of cancer patients using its radio-immunoguided surgery (RIGS) technology. RIGS involves injecting the patient with an agent targeted at cancer antigens and receptors and using this marker to locate small amounts of cancerous tissue. According to NeoProbe, the new patent covers the location of additional tissue not found by any other way. This can improve determination of the stage of a patient's cancer. The patent is the third granted for the RIGS technology this year.